Greenwich LifeSciences, Inc.
GLSI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.12 | -1.16 | -0.34 | -0.52 |
| FCF Yield | -4.97% | -4.79% | -3.16% | -1.36% |
| EV / EBITDA | -9.00 | -13.75 | -22.75 | -62.63 |
| Quality | ||||
| ROIC | -631.87% | -139.21% | -60.85% | -17.14% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.46 | 0.73 | 0.79 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -12.16% | -4.49% | -44.47% | -272.22% |
| Safety | ||||
| Net Debt / EBITDA | 0.26 | 0.75 | 1.68 | 5.92 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -118,992.43 | -3,584.52 | -22,316.84 | -22,316.84 |